News
What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and Scaling Psychedelic Care
4+ hour, 40+ min ago (243+ words) Explore our " Q1 2026 Psychedelic Pipeline Bullseye Charts. Dr. Brian Barnett is a staff psychiatrist at Cleveland Clinic's Center for Behavioral Health and the Clinical Director of the Cleveland Clinic Psychiatric Treatment-Resistance Program. He has served as principal investigator on clinical trials…...
“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour
1+ week, 6+ hour ago (262+ words) Explore our " Q1 2026 Psychedelic Pipeline Bullseye Charts. In this conversation, Nemeroff talks about how that ibogaine programme came together and what his group hopes to learn, as well as a broader look at the centre's psychedelic research portfolio, unanswered questions he…...
The Psychedelic Practitioner Issue 3: Dosing
1+ mon, 2+ week ago (1678+ words) Welcome to the third issue of The Psychedelic Practitioner, a publication for the evolving practice of psychedelic care. This is the second instalment in a three-part series, with the next Issue, focusing on Integration. As a reminder, Issues are currently…...
BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions
1+ mon, 1+ week ago (266+ words) This morning,Compass Pathways shared a highly anticipated topline readout that provides a first look at how patients with treatment-resistant depression (TRD) fared in its second, larger (N=581) Phase 3 study of synthetic psilocybin (COMP360). Notably, the present study (COMP006) administered two doses…...